SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Revenue for the quarter ended  March 2023 of Rs. 19390.48 millions grew by 8.60 % from Rs. 17855.44 millions.The Net Loss for the quarter ended March 2023 is Rs. -1374.69 millions as compared to Net Profit of Rs. 2055.97 millions of corresponding quarter ended March 2022OP of the company witnessed a marginal growth to 4506.36 millions from 3405.67 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 19390.48 17855.44 8.60 82206.62 81415.81 0.97 82206.62 81415.81 0.97
Other Income 2329.65 1789.82 30.16 9859.39 6146.28 60.41 9859.39 6146.28 60.41
PBIDT 4506.36 3405.67 32.32 24587.06 23028.49 6.77 24587.06 23028.49 6.77
Interest 588.60 740.10 -20.47 2068.16 2360.41 -12.38 2068.16 2360.41 -12.38
PBDT -2665.96 2665.57 -200.01 17560.22 24971.41 -29.68 17560.22 24971.41 -29.68
Depreciation 467.29 417.72 11.87 1841.48 1596.95 15.31 1841.48 1596.95 15.31
PBT -3133.25 2247.85 -239.39 15718.74 23374.46 -32.75 15718.74 23374.46 -32.75
TAX -1758.56 191.88 -1016.49 3631.05 3396.57 6.90 3631.05 3396.57 6.90
Deferred Tax -2605.10 -210.77 1135.99 -238.26 -714.21 -66.64 -238.26 -714.21 -66.64
PAT -1374.69 2055.97 -166.86 12087.69 19977.89 -39.49 12087.69 19977.89 -39.49
Equity 282.17 282.17 0.00 282.17 282.17 0.00 282.17 282.17 0.00
PBIDTM(%) 23.24 19.07 21.84 29.91 28.29 5.74 29.91 28.29 5.74

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×